drugset / Trial / NCT00252824

STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma

NCT00252824 ↗

Phase 3 Completed 1000 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with conventional stepwise treatment according to asthma treatment guidelines in patients with persistent asthma

Timeline

Start
2005-07
Primary completion
—
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide/formoterol Unknown 4.5 mg Inhaled
Subject Budesonide/formoterol Unknown 160 mg Inhaled

Indications